Guangyao Liu

Dr. Guangyao Liu


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in Bioactive Materials
Verified
Journal Article
Open access
TZTongtong Zhu
Tongtong Zhu
YCYutao Cui
Yutao Cui
MZMingran Zhang
Mingran Zhang
DZDuoyi Zhao
Duoyi Zhao
GLGuangyao Liu
Guangyao Liu
Jianxun DingJianxun Ding
Jianxun Ding
Osteonecrosis, which is typically induced by trauma, glucocorticoid abuse, or alcoholism, is one of the most severe diseases in clinical orthopedics. Osteonecrosis often leads to joint destruction, and arthroplasty is eventually required. Enhancement of bone regeneration is a critical management strategy employed in osteonecrosis therapy. Bone tissue engineering based on engineered three-dimensional (3D) scaffolds with appropriate architecture and osteoconductive activity, alone or functionalized with bioactive factors, have been developed to enhance bone regeneration in osteonecrosis. In this review, we elaborate on the ideal properties of 3D scaffolds for enhanced bone regeneration in osteonecrosis, including biocompatibility, degradability, porosity, and mechanical performance. In addition, we summarize the development of 3D scaffolds alone or functionalized with bioactive factors for accelerating bone regeneration in osteonecrosis and discuss their prospects for translation to clinical practice.

30 January 2023 in Advanced Science
Verified
Journal Article
Open access
XWXukai Wang
Xukai Wang
MZMingran Zhang
Mingran Zhang
TZTongtong Zhu
Tongtong Zhu
QWQiuhua Wei
Qiuhua Wei
GLGuangyao Liu
Guangyao Liu
Jianxun DingJianxun Ding
Jianxun Ding
Osteomyelitis is a destructive disease of bone tissue caused by infection with pathogenic microorganisms. Because of the complex and long‐term abnormal conditions, osteomyelitis is one of the refractory diseases in orthopedics. Currently, anti‐infective therapy is the primary modality for osteomyelitis therapy in addition to thorough surgical debridement. However, bacterial resistance has gradually reduced the benefits of traditional antibiotics, and the development of advanced antibacterial agents has received growing attention. This review introduces the main targets of antibacterial agents for treating osteomyelitis, including bacterial cell wall, cell membrane, intracellular macromolecules, and bacterial energy metabolism, focuses on their mechanisms, and predicts prospects for clinical applications.

20 August 2021 in Bioactive Materials
Verified
Journal Article
Open access
TZTongtong Zhu
Tongtong Zhu
MJMengyang Jiang
Mengyang Jiang
MZMingran Zhang
Mingran Zhang
LCLiguo Cui
Liguo Cui
XYXiaoyu Yang
Xiaoyu Yang
XCXuesi Chen
Xuesi Chen
Osteonecrosis is a common orthopedic disease in clinic, resulting in joint collapse if no appropriate treatment is performed in time. Core decompression is a general treatment modality for early osteonecrosis. However, effective bone regeneration in the necrotic area is still a significant challenge. This study developed a biofunctionalized composite scaffold (PLGA/nHA30VEGF) for osteonecrosis therapy through potentiation of osteoconduction, angiogenesis, and a favorable metabolic microenvironment. The composite scaffold had a porosity of 87.7% and compressive strength of 8.9 MPa. PLGA/nHA30VEGF had an average pore size of 227.6 μm and a water contact angle of 56.5° with a sustained release profile of vascular endothelial growth factor (VEGF). After the implantation of PLGA/nHA30VEGF, various osteogenic and angiogenic biomarkers were upregulated by 2–9 fold compared with no treatment. Additionally, the metabolomic and lipidomic profiling studies demonstrated that PLGA/nHA30VEGF effectively regulated the multiple metabolites and more than 20 inordinate metabolic pathways in osteonecrosis. The excellent performances reveal that the biofunctionalized composite scaffold provides an advanced adjuvant therapy modality for osteonecrosis.

26 April 2022 in MethodsX
Verified
Journal Article
Open access
TZTongtong Zhu
Tongtong Zhu
MJMengyang Jiang
Mengyang Jiang
MZMingran Zhang
Mingran Zhang
LCLiguo Cui
Liguo Cui
XYXiaoyu Yang
Xiaoyu Yang
XCXuesi Chen
Xuesi Chen
Osteonecrosis is a common orthopedic disease in clinic, resulting in joint collapse if appropriate treatment is not given in time. The clinical usage of high-dose steroid is one of the common causes of osteonecrosis. In several studies, the intravenous injection of steroid with or without lipopolysaccharide is the most commonly used strategy to construct osteonecrosis animal model. However, the injection dose, frequency, and interval of steroid and validation of successful model construction lack generally accepted protocol, and the survival and model formation rates are unsatisfactory. We have optimized the construction protocol of osteonecrosis animal model based on the previously reported ones and established a mature animal model of osteonecrosis for future studies. • A rabbit model of osteonecrosis was constructed by multiple injections of high-dose methylprednisolone. • The multidisciplinary biomedical examinations demonstrated the successful construction of osteonecrosis model in the rabbit.

12 September 2025 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
XWXukai Wang
Xukai Wang
QXQinli Xu
Qinli Xu
JHJinzheng Huang
Jinzheng Huang
YGYating Gao
Yating Gao
FZFangliang Zheng
Fangliang Zheng
GLGuangyao Liu
Guangyao Liu

31 October 2025 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
HWHaitian Wang
Haitian Wang
TZTongtong Zhu
Tongtong Zhu
KYKunpeng Yang
Kunpeng Yang
CXChenkai Xu
Chenkai Xu
ZZZhaoyi Zhang
Zhaoyi Zhang
HRHongge Ren
Hongge Ren
Osteosarcoma (OS), the most prevalent primary malignant bone tumor, disproportionately affects adolescents and is marked by rapid progression and a high rate of pulmonary metastasis. Despite advances in multimodal treatment, outcomes remain dismal for metastatic or relapsed disease, largely due to chemoresistance, immune evasion, and the heterogeneous tumor microenvironment (TME). Increasing evidence underscores the immunoregulatory complexity of osteosarcoma, characterized by immunosuppressive myeloid-derived populations, dysfunctional lymphocyte infiltration, and exosome-mediated immune escape. While immune checkpoint inhibitors have revolutionized treatment in several malignancies, their impact in osteosarcoma remains modest, highlighting the need for combinatorial strategies. Emerging approaches such as adoptive T cell therapies, tumor vaccines, and CAR-T cell interventions are being explored to overcome the “cold” immune milieu. Furthermore, single-cell transcriptomics has shed light on cellular interactions within the osteosarcoma TME, offering insights into resistance mechanisms and potential biomarkers. This review provides a comprehensive overview of the immunological landscape of osteosarcoma and highlights current and emerging immunotherapeutic strategies aimed at improving clinical outcomes in this challenging malignancy.